bluebird bio, Inc.
(NASDAQ : BLUE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.37%72.851.0%$2085.84m
AMGNAmgen, Inc. -0.11%198.271.3%$912.74m
REGNRegeneron Pharmaceuticals, Inc. -0.62%449.522.6%$775.54m
BIIBBiogen, Inc. -2.69%296.751.5%$711.86m
MRNAModerna, Inc. 7.55%30.050.0%$640.21m
VRTXVertex Pharmaceuticals, Inc. -3.23%217.241.9%$526.89m
ILMNIllumina, Inc. -1.96%269.053.5%$482.68m
ALXNAlexion Pharmaceuticals, Inc. -2.47%84.012.0%$265.76m
AAgilent Technologies, Inc. -3.61%71.061.6%$237.61m
EXASEXACT Sciences Corp. -4.91%57.9021.0%$205.46m
INCYIncyte Corp. -5.60%68.962.5%$167.54m
SGENSeattle Genetics, Inc. -5.92%109.276.1%$162.29m
BMRNBioMarin Pharmaceutical, Inc. -3.79%79.514.3%$160.35m
NVAXNovavax, Inc. 2.43%13.05114.7%$149.95m
CODXCo-Diagnostics, Inc. -2.66%9.150.0%$148.50m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.